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Despite the presence of frequent and complex ventricular 
arrhythmias, must patients with chmnic congestive heart 
failure probably should not be given antiarrhylhmic agents 
for the treatment of asymptomatic ventricular rhythm dis 
turbances. In patients who have symptomatic ventricular 
arrhythmias, the goals of antiarrhythmic therapy are the 
supressian of symptoms and the prevention of sudden car- 
diac death. In patients with asymptomatic ventricular 
arrhythmias, however, treatment can onlv be directed at 
preknting lethal arrhythmic events. U&rtunately, it is 
difficull to establish a loeical rationale for treathw the 
asymptomatic patient be&e it is not known whether the 
suppression of asymptomatic ventricular arrhythmias will 
prevent sudden death. This uncertainty must be weighed 
winst the knowled!ae that all antiarrhythmic drues nroduce 
s;bstantial side e&s (including the r&k ofena&b&ng the 
arrhythmia) that can be lethal. Thus. althoueh some uatients _ . 
witd chronic heart failure are likely to benefit from anti- 
arrhythmic theraw. it is imuortanl to analwe the risk/benefit 
ratid associated &h ihe &tment of these patients. 
Risk of asymptomatic arrhythmias in cbronlc heari fedture. 
The frequency and complexity of ventricular arrhythmias 
@.rticularly nonsustained ventricular tachycardia) are major 
risk factors for sudden cardiac death (l-14). although the 
precise nature of the relation between nonsustained ventricu- 
lar tachycardia nd sudden cardiac death remains unclear. It 
is possible that nonsustained ventricular tachycardia may 
actually trigger the nnset of sustained ventricular tachycardia 
or fibrillalion; it may itself become sustained at a given point 
in time (although such a transformation is uncanmun in my 
experience) or it may merely w-a as a marker of a ventricle 
that is capable of supporting more serious arrhythmias. 
sudden death? II is important to remember that episodes of 
nonsustained ventricular tachycardia in asymptomatic pa- 
tients tend to occur infrequently. less than live times daily. 
for example, and are usually three to five complexes in 
duration with a rate of 160 beatslmin or less. Most inverti- 
gators have been unable to identify characteristics of the 
tachycardia that predict the subsequent occurrence of a 
sustained tachyarrhythmio. Although Meinenz et al. (12) 
reported an assosiation between the frequency of non- 
sustained ventricular tachycardia nd the subsequent clinical 
outcome, this observation has not been confirmed by other 
studies. It is also important to remember that the rate of 
ventricular tachycardia i Iften variable in patients with 
asymptomatic arrhythmias. Kammerling et al. (15) showed 
that there was little correlation between the rate of non- 
sustained venlricular tachycardia and the rate of sustained 
ventricular tachycardia in the wne patient. Indeed. the 
more frequent the episodes of ventricular tachycardia in the 
individual patient, the nwre marked was the variability in 
tachycardia rate (15). It is not surprising. therefore. that it 
has been hard to define a correlation between the rate of 
tachycardia nd the occurt-ellce of sudden cardiac death. 
Hence. although it is clear that patients with poor left 
ventricular function who have asymptomatic ventricular 
arrhythmias (especially nonsustained ventricular tachycar- 
dia) are at substantial risk for sudden cardiac death. neither 
the duration, the rate nor the frequency of the ventricular 
arrhythmias or tachycardia ppears to predict the likelihood 
of? subsequent lethal arrhythmic event. Such uncertainty 
raises important questions about whether we can accurately 
identify high risk patient subsets on the basis of the arrhyth. 
miss recorded during routine clinical ambulatory electrocw 
diography. 
Risk of antiarrhythmic theraw in chronic heart failure. 
The risks of antiarrhythmic drugiherapy are numerous and 
include the possibility of minor and serious side effects as 
well as the costs of drug therapy and associated hospitaliza- 
tions. The most serious adverse reaction of antiarrhythmic 
drugs is the risk of life-threatening ventricular proarrhyth- 
mix, which is particularly high in the patient witb congestive 
heart failure (X-20). Most proarrhythmic events occur early 
duringthecourseoftherapy. Inarecentstudy by Minardoet 
al. f20). antiarrhvthmic drugs (most commonly. quinidine) 
were implicated.in provoking 39 episodes oi &ntricular 
fibrillation in 29 patients, none of whom had a history ofthis 
serious arrhythmia. For quinidine, prcainamide and disopy- 
ramide, the median duration of lherapy before the occur- 
rence of ventricular fibrillation was only 3 days, and >70?? 
of all proxrbythmic events occurred within 5 days of initi- 
ation of treatment. Similar findings with respect to 
pmarrhythmia have been reported by Stanton et al. (19). 
Another important adverse reaction of ontiarrhythaic 
drug therapy is the risli o/worsening heartfailwe. Nearly all 
antiarrhythmic agents can produce notable cardiodepressant 
:tTects--some worse than others-parricularly in the patient 
with a history of congestive heart failure. Such effects may 
produce clinical exacerbation of the heart failure stat% 
which may be difficult to distinguish from changes that may 
result from progression of the underlying disease. Conse- 
quently. many clinically important negative inotropic reac- 
tions to antiarrbythmic therapy probably pass undetected or 
are attributed to changes in concomitant medications. If 
these cardiodepressant eiTects become marked, pitients may 
not be able to tolerate any episodes of ventricule’ tachycar- 
dia. even if they occur at a rate that would othe wise have 
been well tolerated had the myocardium tmt been pharma- 
cologically depressed. 
Brrnrrse of rhe early rist ofproarrhyrhmia and worsening 
lreorr fnilare. in-hospital iniriarion qf antiorrhyrhmic rheropy 
should be srrongly considered for mosr pnrienrs n~ith con- 
penivr heorr failure. Unfortunately, this approach adds a 
maior cost to the total expense oftreatment. This expense is 
in bsrt related to the &nount of time necessary for any 
antiarrhythmic drug to reach steady state conditions because 
both the efficacy and side effects are best evaluated at this 
point. The time required to reach steady state varies consid- 
erably among agents. For prcainamide. quinidine and dis- 
opyramide. only t 10 2 days may be required to attain sleady 
state conddmns at :I given dose in most patients. In contrast, 
drugs such as tocain~de, mexiletine. flecainide and en&tide 
require additional days of observation in the hospital to 
en&e patient safety is the dosage of these drugs is gradu- 
ally increased. 
The ris!u end costs of anliarrhylhmic drug therapy are 
pnrticr&wiy high during ~eam~nr with amiodarone. Like 
other antiarrhythmic agents. amiodarone can exacerbate 
arrhythmias and produce clinically important negative ino- 
tropic effects. In addition, because of its potential toxicity. 
treatment with amiodarone requires extensive laboratory 
testing to maintain effective surveillance of the patient for 
adverse reactions. During the 1st year of amicdarone ther- 
apy. our current recommendation is to perform a baseline 
pulmonary function test: chest radiograph and liver function 
tests before treatment and again every 3 months; in addition. 
thyroid function tests are assessed at baseline and every 6 
months. At our institution. the cost of these tests during the 
1st year would be approximately %1,2W. It is difficult to 
ration&e this enormous cost and potential toxicity for the 
individual patient to permit the use of this drug, which has 
not been approved by the Food and Drug Administration for 
the treatment of asymptomatic ventricular arriw:bmizs,. 
In summary, onkv~hyrhmic therapy offers potential ben- 
&that areoffser by proved risb. Such aconclusion argues 
against the empiric use of antiarrhythrrdc drugs in the 
treatment of asymptomatic ventricular arrhythmias in most 
patients with chronic heart failure. This conclusion leaves 
open the possibility that some patients with heart failure 
could benefit from treatment ifan approach were available to 
identify patients at high risk of sudden death. 
Approach to Ute identification of high risk patients. It is 
unknown whether therapy for any patient with asympto- 
matic ventricular arrhythmias will prolong life. In the ab- 
sence of such sumwting data, we are cmspectively evalu- 
ating an approxh’to th; management of tbi asymptomatic 
patienl with nonsustained ventricular tachycardia. After the 
detection of this arrhythmia during ambulatory e:cctrocar- 
diographic monitoring. patients who arc being considered for 
treatment undergo an asswsment of lcfl ventricular ejection 
fraction as well as signal-averaged electrocardiography. A 
high risk patient is identified from these initial tests if he or 
she has an ejection fraction of <4G% or an abnormal 
signal-averaged electrocardiogram, or both (21-27). These 
patients then undergo pmgmmmed right ventricular slimu- 
lation using two sites, three pacing cycle lengths and up to 
three extrastimuli, recognizing that several limitations of 
electrophysiologic testing are present in these individuals 
(28-31). Antianhylhmic drug therapy is considered if sus. 
tained monomorphic ventricular tachycardia is induced or if 
ventricular fibrillation is induced using only one or two 
ventricular extrastimuli: subsequent drug therapy is guided 
by lbe results of serial clcctrophysiologic-pharmacologic 
testing. Because the benefits of treatment utilizing this 
approach in asymptamatic patients remain uncertain, we do 
not utilize aggressive therapeutic interventions uch as amio- 
damne, surgery or implantable devices. Of note, in patients 
with nonischemic cardiomyopathy and noninducibility of 
ventricular tachycardia, antiarrhythmic drug therapy is not 
precluded because the sensitivity for initiation of ventricular 
tachycardia in these patients is less than for patients with 
coronary artery disease (31). 
Condusions. Because antiarrhytbmic agents have many 
potentially harmful effects, it is difficult to recommend their 
routine use in all (or even most) patients who have left 
ventricular dysfunction and asymptomatic ventricular 
arrhythmias. Although antiarrhythmic therapy will probably 
be beneficial in some patients, identification ofthis high-risk 
subset requires further study. If antianhythmic drugs arc 
administered in this setting, therapy should be initiated in the 
hospital to minimize prowrhythmic complications. 
PRYSrOWSKY 283 
ANTlARRHYrHMlC DRUGS AND CONGESnVE HEART FAILURE 
